Compare · Head-to-head
CJC-1295 vs IGF-1 LR3.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with CJC-1295, then use the table to confirm fit.
CJC-1295 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Primary fit | muscle growth & strength and fat loss & metabolism comparisons | muscle growth & strength research where you want a clear starting point |
| Evidence | Tier B | Tier C |
| Risk | high | extreme |
| Experience level | intermediate | advanced |
| Budget tier | mid | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Muscle Growth & Strength |
| What users compare it for | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Growth factor signaling; muscle growth narratives in gray market. High mitogenic/glucose risk. |
| Onset timeline | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | Acute metabolic effects possible; anabolic narratives are speculative in consumer context. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Adverse effects | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Hypoglycemia, mitogenic signaling, growth-factor class risks. |
| Contraindications | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Active malignancy (by analogy to growth factor class). High interaction potential with insulin/glucose-lowering agents. |
| Interaction notes | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | High interaction potential with insulin/glucose-lowering agents; avoid prescriptive guidance. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA status unclear |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54 | No age guidance yet |
| Life-stage note | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Not yet documented |
| Monitoring burden | high | Not specified |
| Follow-up cadence | Reassess at startup and then roughly every few months if continuing. | Not yet documented |
05 · Cost & sourcing
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Typical cycle cost | $143.98 | $97.99 |
| Estimated monthly cost | $47.99 | $130.65 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| Tracked vendor listings | 3 listings | 2 listings |
| Sourcing note | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.